Immunocore Holdings plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Immunocore Holdings plc (IMCR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of -$179.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-25
- Immunocore Holdings plc effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was -$179.00K.
- Immunocore Holdings plc effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was -$43.00K.
- Immunocore Holdings plc effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was -$567.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | -$179.00K 10-K · filed 2026-02-25 |
| 2024-12-31 | -$43.00K 10-K · filed 2026-02-25 |
| 2023-12-31 | -$567.00K 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |